<SEC-DOCUMENT>0001437749-23-000499.txt : 20230105
<SEC-HEADER>0001437749-23-000499.hdr.sgml : 20230105
<ACCEPTANCE-DATETIME>20230105164004
ACCESSION NUMBER:		0001437749-23-000499
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221229
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230105
DATE AS OF CHANGE:		20230105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genprex, Inc.
		CENTRAL INDEX KEY:			0001595248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				900772347
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38244
		FILM NUMBER:		23512022

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
		BUSINESS PHONE:		512-537-7997

	MAIL ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gnpx20230103_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:gnpx="http://www.gnpx.com/20221229"><head>
	<title>gnpx20230103_8k.htm</title>
	<!-- Created by RDG Portal -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20238K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20238K" name="dei:EntityCentralIndexKey">0001595248</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="gnpx-20221229.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20238K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-12-29</xbrli:startDate>
<xbrli:endDate>2022-12-29</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>UNITED STATES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Washington, D.C. 20549</b>&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#xa0; &#xa0;</div>

<div style="background-color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;line-height:.15;margin:0pt 7.2pt;text-align:center;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>FORM <ix:nonNumeric contextRef="d20238K" name="dei:DocumentType"><b><b>8-K</b></b></ix:nonNumeric></b>&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#xa0; &#xa0;&#xa0;</div>

<div style="background-color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;line-height:.15;margin:0pt 7.2pt;text-align:center;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>PURSUANT TO SECTION 13 OR 15(d)</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span style="text-decoration: underline;"><b>December 29, 2022</b></span></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">Date of report (Date of earliest event reported)</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt 7.2pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityRegistrantName"><span style="text-decoration: underline;"><b>GENPREX, INC.</b></span></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>&#xa0;</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="text-decoration: underline;"><b>Delaware</b></span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:29.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityFileNumber"><span style="text-decoration: underline;"><b>001-38244</b></span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityTaxIdentificationNumber"><span style="text-decoration: underline;"><b>90-0772347</b></span></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">incorporation or organization)</div>
			</td>
			<td style="vertical-align:top;width:29.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File Number)</div>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Identification Number)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">&#xa0;</td>
			<td style="vertical-align:top;width:29.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:35%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline;"><b><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressAddressLine1"><span style="text-decoration: underline;"><b>3300 Bee Cave Road, #650-227</b></span></ix:nonNumeric>, <ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressCityOrTown"><span style="text-decoration: underline;"><b>Austin</b></span></ix:nonNumeric>, <ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressStateOrProvince"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>TX</b></span></b></span></ix:nonNumeric></b></span></div>
			</td>
			<td style="vertical-align:top;width:29.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressPostalZipCode"><span style="text-decoration: underline;"><b>78746</b></span></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</div>
			</td>
			<td style="vertical-align:top;width:29.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Zip Code)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">Registrant&#8217;s telephone number, including area code: <span style="text-decoration: underline;"><b>(<ix:nonNumeric contextRef="d20238K" name="dei:CityAreaCode"><span style="text-decoration: underline;"><b>512</b></span></ix:nonNumeric>) <ix:nonNumeric contextRef="d20238K" name="dei:LocalPhoneNumber"><span style="text-decoration: underline;"><b>537-7997</b></span></ix:nonNumeric></b></span></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Securities registered pursuant to Section&#xa0;12(b) of the Act:</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:37.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:1.3%;">&#xa0;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Trading</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:1.3%;">&#xa0;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:44.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:37.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1.3%;">&#xa0;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20238K" name="dei:TradingSymbol">GNPX</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1.3%;">&#xa0;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:44.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The <ix:nonNumeric contextRef="d20238K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Emerging growth company&#xa0;<ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;<ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: left;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">On December 29, 2022, Genprex, Inc. (&#8220;Genprex&#8221;) and the University of Pittsburgh - Of the Commonwealth System of Higher Education (&#8220;UP&#8221;) entered into an Exclusive License Agreement (the &#8220;UP License Agreement&#8221;), pursuant to which UP granted to Genprex a worldwide, exclusive license under a certain patent&#xa0;and related technology, referred to collectively as the licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">The UP License Agreement authorizes Genprex to make, have made, use and sell the licensed technology and to practice the patent rights in the field of diabetes therapy. Genprex may enter into sublicensing arrangements for the rights, privileges and licenses granted under the UP License Agreement upon the prior written approval of UP. Genprex agreed to use its diligent and commercially reasonable efforts to bring the licensed technology to market, to continue active, diligent marketing efforts for the licensed technology throughout the term of the UP License Agreement, and to achieve certain milestones within specified time periods. Genprex agreed to submit annual progress reports to UP and, beginning in the year of the first commercial sale&#xa0;of the licensed technology, quarterly reports of manufacturing, sales and sublicense activities to UP including information as would allow the calculation of amounts owing to UP on account of such activities, as well as Genprex&#8217;s calculation of such amounts.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">UP has reserved the royalty-free, nonexclusive right to practice the patent rights and know-how and to use the licensed technology for non-commercial education and research purposes, and Genprex agreed to sell licensed technology to UP and its affiliates upon request at the price and terms as are made available to Genprex&#8217;s most favored customer. The licenses granted to Genprex under the UP License Agreement are subject to the rights of the U.S. government, which may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the patent rights throughout the world.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">As consideration for the UP License Agreement, Genprex agreed to pay UP an initial license fee, annual maintenance fees, running single digit royalties, minimum annual royalties in a fixed cash amount, a low double digit percentage share of non-royalty sublicense income, and certain milestone payments up to an aggregate of approximately $4,000,000,&#xa0;as well as patent prosecution expenses incurred prior to and after the effective date of the UP License Agreement.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">The UP License Agreement remains in effect until the later of 20 years after the first commercial sale of the licensed technology or the expiration of the last valid claim of the patents licensed under the UP License Agreement. UP may terminate the agreement in the event of Genprex&#8217;s uncured default, failure to achieve the specified milestones within the specified time period, or intentional practice of the licensed patent rights or know-how outside the field of diabetes therapy, or if Genprex ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the relief of debtors. Genprex may terminate the UP License Agreement upon six months prior written notice to UP and payment of all amounts accrued or due to UP through the effective date of termination.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">The foregoing description of the material terms of the UP License Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, reference to the UP License Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;"><b>Item 7.01 Other Events.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;"><i>Press Releases</i></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">On January 4, 2023 and January 5, 2023, the &#8220;Company issued press releases.&#xa0; The full text of the press releases are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2, respectively.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1 and Exhibit 99.2, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: justify;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><b>Item 9.01: Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">(d) Exhibits.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Number</b></div>
			</td>
			<td style="vertical-align:bottom;width:4.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:86.2%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">10.1#</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_460640.htm" style="-sec-extract:exhibit;">Exclusive License Agreement, dated December 29, 2022.</a></td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">99.1</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_461280.htm" style="-sec-extract:exhibit;">Press Release, dated January 4, 2023.</a></td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">99.2</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_461281.htm" style="-sec-extract:exhibit;">Press Release, dated January 5, 2023.</a></td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">104</td>
			<td style="vertical-align:middle;width:4.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:86.2%;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"># Certain portions of this exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K and Genprex, Inc. agrees to furnish supplementally to the U.S. Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request. The portions of this exhibit that were omitted by means of marking such portions with asterisks because the identified portions are both (i) not material, and (ii) the type that registrant treats as private or confidential.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.3pt;text-align:left;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.3pt; text-align: center;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#xa0;</td>
			<td colspan="2" style="vertical-align:top;border-bottom: 1px #000000;;width:33.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>GENPREX, INC.</b></div>
			</td>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:11.8%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#xa0;</td>
			<td style="vertical-align:top;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:29.6%;">&#xa0;</td>
			<td style="vertical-align:top;width:11.8%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: January 5, 2023</div>
			</td>
			<td style="vertical-align:top;width:3.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</div>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>/s/ Ryan Confer</i></div>
			</td>
			<td style="vertical-align:top;width:11.8%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#xa0;</td>
			<td style="vertical-align:top;width:3.5%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ryan Confer</div>
			</td>
			<td style="vertical-align:top;width:11.8%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 55.1%;">&#xa0;</td>
			<td style="vertical-align: top; width: 3.5%;">&#xa0;</td>
			<td style="vertical-align: top; width: 29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer)</div>
			</td>
			<td style="vertical-align: top; width: 11.8%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_460640.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_460640.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">EXHIBIT 10.1</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"><b>CERTAIN IDENTIFIED INFORMATION MARKED WITH </b>&#8220;<b>[***]</b>&#8221;<b> HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>EXCLUSIVE LICENSE AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">This Exclusive License Agreement (&#8220;Agreement&#8221;) is made and entered into as of as of the date of the last signature to this Agreement (&#8220;Effective Date&#8221;), by and between the University of Pittsburgh &#8211; Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania&nbsp; 15260 (&#8220;University&#8221;), and Genprex, Inc., a Delaware corporation, with its principal business at 3300 Bee Cave Road, Suite 650-227, Austin, Texas 78746 (&#8220;Licensee&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">WHEREAS, University is the owner by assignment from the inventors of certain patent rights, entitled &#8220;Insulin promoter for gene therapy for type 2 diabetes mellitus&#8221; as further defined in Section 1.10 below and more particularly identified in Exhibit A attached hereto (&#8220;Patent Rights&#8221;) developed by George Gittes, et al, of the University faculty, and of certain know-how as further defined in Section 1.4 below and more particularly identified in Exhibit D attached hereto (&#8220;Know-How&#8221;);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">WHEREAS, University has the right to grant licenses under such Patent Rights and Know-How;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">WHEREAS, University desires to have the Patent Rights and Know-How utilized in the public interest;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">WHEREAS, Licensee desires to obtain a license under the Patent Rights and Know-How upon the terms and conditions hereinafter set forth, and Licensee shall commit itself to a thorough, vigorous and diligent program of exploiting the Patent Rights so that public utilization results therefrom.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto, intending to be legally bound, agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 1 </b>&#8211;<b> DEFINITIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">For purposes of this Agreement, the following words and phrases shall have the following meanings:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Affiliate&#8221;&nbsp;shall mean, with respect to University, any clinical or research entity that is operated or managed as a facility under the UPMC Health System, whether or not owned by University. With respect to Licensee, &#8220;Affiliate&#8221;&nbsp;means any company or legal entity that directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Licensee but only for as long as such control exists.&nbsp;&nbsp;For this definition, &#8220;control&#8221;&nbsp;means the possession, directly or indirectly, of the power to direct or cause the direction of the affairs or management of an entity, whether through the ownership of voting securities, by contract or otherwise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Field&#8221;&nbsp;shall mean diabetes therapy.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;FDA&#8221;&nbsp;means the United States Food &amp; Drug Administration or its successor.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.4</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Know-How&#8221;&nbsp;means (a) the University information set forth on Exhibit D and existing on the Effective Date, (b) whether or not covered by a Valid Claim in Patent Rights, and (c) useful or necessary to make, have made, use or sell the Licensed Technology in the Field.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.5</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Licensee&#8221;&nbsp;shall mean Genprex, Inc.&nbsp;&nbsp;Licensee may extend the license granted herein to any Affiliate provided that the Affiliate agrees in writing to be bound by this Agreement to the same extent as Licensee.&nbsp;&nbsp;For the sake of clarity, any specific reference to &#8220;Licensee&#8221;&nbsp;in any provision of this Agreement shall include such Affiliate regardless of whether a specific reference to an &#8220;Affiliate&#8221;&nbsp;is made in such provision.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.6</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Licensed Technology&#8221;&nbsp;shall mean any product or component or part thereof which is:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Covered in whole or in part by a Valid Claim in the Patent Rights in the country in which any such product, component, or part thereof is made, used or sold or in which any such service is used or sold;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Manufactured by using a process or is employed to practice a process which is covered in whole or in part by a Valid Claim in the Patent Rights in the country in which any such process that is included in Licensed Technology is used or in which such product, component, or part thereof or service is used or sold; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Manufactured by or otherwise makes use of Know-How.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.7</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Net Sales&#8221;&nbsp;shall mean Licensee&#8217;s and any sublicensee&#8217;s invoice price from the Sale of Licensed Technology hereunder less the sum of the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Actual cost of freight or transportation charges or absorption and packing charges, separately stated in such invoice;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Actual trade, quantity or cash discounts allowed, if any;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sales taxes, tariff duties, use taxes, and other taxes, excluding income taxes, separately stated on each invoice; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Other amounts actually refunded, allowed or credited due to rejection, returns, or reperformance of services, but not exceeding the original invoiced amount.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 52pt;">Sales, transfers, or other dispositions of any Licensed Technology, at or below cost, for charitable, promotional (including samples), pre-clinical, clinical, or regulatory purposes will be excluded from Net Sales.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.8</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Non-Commercial Education and Research Purposes&#8221;&nbsp;shall mean use of Patent Rights and/or Know-How (including distribution of biological materials covered by the Patent Rights) in the Field for academic research or other not-for-profit scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the Patent Rights in the production or manufacture of products for sale or the performance of services for a fee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.9</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Non-Royalty Sublicense Income&#8221;&nbsp;shall mean execution fees, maintenance fees, milestone fees and all other non-royalty payments received by Licensee from its sublicensees pursuant to any sublicense granted pursuant to Section 2.5 hereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 14%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.10</p>
			</td>
			<td style="vertical-align: top; width: 82%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Patent Rights&#8221;&nbsp;shall mean University intellectual property described below and assigned to University:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The United States and foreign patents and/or patent applications listed in <u>Exhibit</u><u>&nbsp;</u><u>A</u>;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any non-provisional patent applications that claim priority to any provisional patent application listed in <u>Exhibit A</u>;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any and all foreign patent applications, foreign patents or related foreign patent documents that claim priority to the patents and/or patent applications listed in <u>Exhibit A</u>;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any and all divisionals, continuations, reissues, re-examinations, renewals, substitutions, and extensions of the foregoing; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(e)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any and all patents issuing from the foregoing.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:13.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.11</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Pivotal Trial&#8221;&nbsp;means a controlled pivotal clinical trial of Licensed Technology that is prospectively designed to demonstrate statistically whether such Licensed Technology is effective and safe for use in a particular indication in a manner sufficient to obtain regulatory approval to market such product in the United States, European Union, or other foreign jurisdiction.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:13.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.12</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Territory&#8221;&nbsp;shall mean Worldwide.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:13.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">1.13</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Valid Claim&#8221;&nbsp;shall mean a claim of (i) an issued and unexpired patent which has not been declared invalid or unenforceable in a court of appropriate jurisdiction, withdrawn, abandoned, or revoked, or (ii) a patent application which has not been withdrawn, abandoned, rejected, or revoked and has not been pending for more than six (6) years from the filing date.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 2 </b>&#8211;<b> GRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 14%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.1</p>
			</td>
			<td style="vertical-align: top; width: 82%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Subject to the terms and conditions of this Agreement, University hereby grants to Licensee, to the extent it may lawfully do so, the right and exclusive license in the Territory to make, have made, use and sell the Licensed Technology in the Field and to practice the Patent Rights in the Field for the Term set forth in Article 10 below. Licensee shall not practice the Patent Rights outside of the Field. University reserves the royalty-free, nonexclusive right to practice the Patent Rights and Know-How and to use the Licensed Technology for Non-Commercial Education and Research Purposes. University and any nonprofit or governmental institution also have the right to publish or have published any University information included in the Licensed Technology, Know-How or Patent Rights.&nbsp;&nbsp;This Agreement does not include transfer of any materials.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 14%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.2</p>
			</td>
			<td style="vertical-align: top; width: 82%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Subject to the terms and conditions of this Agreement, University hereby grants to Licensee, to the extent it may lawfully do so, the right and nonexclusive license in the Territory to practice the Know-How in the Field for the Term, unless the Agreement is terminated earlier in accordance with Article 10.&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 14%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.3</p>
			</td>
			<td style="vertical-align: top; width: 82%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The license(s) granted hereby is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. &#167;200, <i>et seq</i>.&nbsp;&nbsp;Pursuant to this law, the United States government may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the Patent Rights throughout the world.&nbsp;&nbsp;Pursuant to 35 U.S.C. &#167;200, <i>et seq</i>.&nbsp;&nbsp;Licensed Technology&nbsp;produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. &#167;204 is granted by the appropriate United States government agencies).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 14%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.4</p>
			</td>
			<td style="vertical-align: top; width: 82%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sublicenses.&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall have the right to enter into sublicensing arrangements for the rights, privileges and licenses granted hereunder upon the prior written approval of each sublicensee by University, except that sublicensees shall not have rights to sublicense.&nbsp;&nbsp;University&#8217;s approval of such sublicensee agreements shall not be unreasonably withheld or delayed.&nbsp;&nbsp;Such sublicense agreements shall include a royalty rate upon sublicensees&#8217;&nbsp;Net Sales in an amount at least equal to the rate set forth in Section 4.l(c).&nbsp;&nbsp;In all such sublicense agreements, Licensee shall impose on the sublicensee an obligation to not practice the Patent Rights or Know-How outside of the Field.&nbsp;&nbsp;Upon the termination of this Agreement and upon the request of any sublicensee,&nbsp;&nbsp;any sublicenses granted prior to either party&#8217;s receipt of any termination notice under this Agreement shall survive termination, provided that such sublicensee: (a) is not at such time in breach of this Agreement; and (b) agrees in writing to assume all of the Licensee&#8217;s applicable obligations under this Agreement through an assumption agreement or amended license Agreement, as appropriate.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee agrees that any sublicense granted by it shall provide that the obligations to University of Articles 2, 7, 8, 9, and Sections 10.2, and 13.1 of this Agreement shall be binding upon the sublicensee as if it were a party to this Agreement.&nbsp;&nbsp;Each sublicense granted by Licensee pursuant to this Agreement shall include an audit right by University of sublicensee of the same scope as provided in Section 5.2 with respect to Licensee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee agrees to forward to University a copy of any and all sublicense agreements promptly upon execution thereof, but in no event later than thirty (30) days after each such sublicense agreement has been executed by both parties thereto; provided however, such sublicense or amendment may be redacted with respect to the sublicensee&#8217;s scientific and technical information.&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">2.5</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The license granted hereunder shall not be construed to confer any rights upon Licensee by implication, estoppel or otherwise as to any intellectual property not specifically set forth in <u>Exhibit A</u>&nbsp;or <u>Exhibit D</u>&nbsp;hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 3 </b>&#8211;<b> DUE DILIGENCE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall use its diligent and commercially reasonable efforts to bring the Licensed Technology to market in the Field as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent marketing efforts for the Licensed Technology throughout the Term of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In addition, Licensee shall adhere to each of the following milestones:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(e)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***]; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(f)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***].</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">3.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee&#8217;s failure to perform in accordance with Section 3.1 or to fulfill on a timely basis any one of the milestones set forth in Section 3.2 hereof shall be grounds for University to terminate this Agreement, and upon termination all rights and interest to the Know-How and Patent Rights shall revert to University.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 4 </b>&#8211;<b> LICENSE CONSIDERATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In consideration of the rights, privileges and licenses granted by University hereunder, Licensee shall pay royalties and other monetary consideration as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Initial license fee, nonrefundable and noncreditable against royalties, of [***] due immediately and payable within ten (10) business days from the Effective Date of this Agreement;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Annual maintenance fees, non-refundable, non-creditable, and not to be prorated against any other payment or royalties due, in the following amounts until the first Net Sale of a Licensed Technology occurs:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align: top; width: 72%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***]; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Running royalties in the following amounts shall become due immediately and shall&nbsp;&nbsp;become payable as set forth in Section 4.2:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align: top; width: 72%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***] of Net Sales of Licensed Technology covered by a Valid Claim of Patent Rights; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***] of Net Sales of Licensed Technology <u>NOT</u> covered by a Valid Claim of Patent Rights, but which uses or was manufactured using Know-How;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Beginning with the first commercial sale of a Licensed Technology, a minimum annual royalty in the amount of [***] per calendar year, but only to the extent such minimum royalty is greater than the aggregate annual royalty computed in accordance with Section 4.1(c) above;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(e)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A share of Non-Royalty Sublicense Income of [***]; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(f)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Milestone payments as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align: top; width: 72%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iii)</p>
			</td>
			<td style="vertical-align: top; width: 72%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***]; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 24%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(iv)</p>
			</td>
			<td style="vertical-align: top; width: 72%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[***].</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All payments pursuant to this Agreement shall be made by check or by wire transfer in United States Dollars without deduction or exchange, collection or other charges and directed to the address, or in the case of wire transfer, to the bank set forth in Article 12.&nbsp;&nbsp;Annual maintenance fees pursuant to Section 4.1(b) hereof shall be paid on the anniversary of the Effective Date of the calendar year in which they are due.&nbsp;&nbsp;Royalty payments pursuant to Section 4.1(c) hereof shall be paid within thirty (30) days after each March&nbsp;31, June 30, September 30 and December 31.&nbsp;&nbsp;Minimum annual royalties pursuant to Section 4.1(d) shall be due December 31 and paid by January 30 following the calendar year in which they are due.&nbsp;&nbsp;Non-Royalty Sublicense Income payments pursuant to Section 4.1(e) hereof shall by paid within thirty (30) days after receipt of payment by Licensee from sublicense. Milestone payments pursuant to Article 4.1(f) shall be paid within thirty (30) days of milestone event date.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Taxes imposed by any foreign governmental agency on any payment to be made to University by Licensee shall be paid by Licensee without deduction from any payment due to University hereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.4</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The balance of any payments pursuant to this Agreement, including those specified in Section 6.2, which are overdue shall bear interest, compounded monthly, calculated from the due date until payment is received at the rate of [***] per annum.&nbsp;&nbsp;Payment of such interest by Licensee shall not negate or waive the right of University to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection with collecting any overdue balance of payments with respect to Licensee&#8217;s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">4.5</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall sell Licensed Technology to University and its Affiliates upon request at such price(s) and on such terms and conditions as such products and/or processes are made available to Licensee&#8217;s most favored customer.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 5 </b>&#8211;<b> REPORTS AND AUDIT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Within thirty (30) days after each March 31, June 30, September 30 and December 31 of each year during the Term of this Agreement beginning in the year of the first commercial sale of Licensed Technology, Licensee shall deliver to University true, accurate and detailed reports of the following information in a form as illustrated in <u>Exhibit B</u>:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Number of Licensed Technology products manufactured and sold by Licensee and all sublicensees;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Total billings for all such products;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accounting for all Licensed Technology used or sold by Licensee and all sublicensees;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Deductions set forth in Section 1.5;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(e)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Total royalties due;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(f)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name and addresses of sublicensees; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(g)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Total Non-Royalty Sublicense Income received during such calendar quarter and total amount of payment due pursuant to Section 4.1(e).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall keep complete, true and accurate books of account, in accordance with generally accepted accounting principles, containing all information that may be necessary for the purpose of showing the amounts payable to University hereunder.&nbsp;&nbsp;Such books of account shall be kept at Licensee&#8217;s principal place of business.&nbsp;&nbsp;Such books of account shall be open at all reasonable times for [***] following the end of the calendar year to which they pertain, and for [***] after the expiration or earlier termination of this Agreement, for inspection by University or its agents for the purpose of verifying Licensee&#8217;s royalty statement or compliance in other respects with this Agreement.&nbsp;&nbsp;The fees and expenses of University&#8217;s representatives shall be borne by University; however, if an error of more than [***] of the total payments due or owing for any year is discovered, then Licensee shall bear University&#8217;s fees and expenses.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">No later than sixty (60) days after December 31 of each calendar year during the Term of this Agreement, Licensee shall provide to University a written annual progress report, as illustrated in <u>Exhibit C</u>, describing Licensee&#8217;s progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding twelve-month period ending December 31.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.4</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Notwithstanding the above, University shall have the right, on an annual basis during the term of this Agreement and for three (3) years after the expiration or termination of this Agreement, to inspect technical and other information from Licensee sufficient to evidence whether and to what extent Licensee is: (a) practicing the Patent Rights, Know-How and/or other University property licensed hereunder; and (b) meeting its diligence obligations under Article 3, above.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">5.5</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall report to the University the date of the first commercial sale of a Licensed Technology within sixty (60) days of occurrence in each country.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 6 </b>&#8211;<b> PATENT PROSECUTION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">6.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">University has or shall apply for, seek prompt issuance of, and maintain during the Term of this Agreement the Patent Rights in the United States and in such foreign countries as may be designated by Licensee in a written notice to University within a reasonable time in advance of the required foreign filing dates.&nbsp;&nbsp;University will confer with Licensee to develop a strategy for the prosecution and maintenance of Patent Rights.&nbsp;&nbsp;Licensee shall have the opportunity to advise and cooperate with University in the prosecution, filing and maintenance of such patents, and to the extent practicable, all documents prepared by University&#8217;s counsel for submission to governmental patent offices will be provided to Licensee for review and comment prior to filing.&nbsp;&nbsp;Licensee shall notify University immediately if, at any time during the term of this Agreement, Licensee or any of its sublicensees does not qualify as a &#8220;small entity&#8221;&nbsp;as provided by the United States Patent and Trademark Office.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">6.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All fees and costs, including attorneys&#8217;&nbsp;fees, relating to the filing, prosecution, maintenance, and post grant proceedings relating to the Patent Rights shall be the responsibility of Licensee, whether incurred prior to or after the Effective Date.&nbsp;&nbsp;Such fees and costs incurred by University prior to the Effective Date in the amount of [***] (&#8220;Pre-agreement Expenses&#8221;) are due on the Effective Date and shall be paid by Licensee within thirty (30) business days of the Effective Date.&nbsp;&nbsp;Fees and costs incurred after the Effective Date, or fees and costs incurred before the Effective Date which are not included in the Pre-agreement Expenses stated above, shall be paid by Licensee within thirty (30) days after receipt of University&#8217;s invoice therefor.&nbsp;&nbsp;Additionally, Licensee shall be liable to University for all of University&#8217;s out-of-pocket filing, prosecution, and maintenance costs (including all attorneys&#8217;&nbsp;fees and costs), for any and all patent prosecution and maintenance actions that will be taken by patent counsel after the Term of this Agreement but in response to any instructions that were sent during the Term of this Agreement from University to patent counsel relating to the Patent Rights.&nbsp;&nbsp;Payments pursuant to this Section 6.2 are not creditable against royalties or any other payment due to University under this Agreement.&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 7 </b>&#8211;<b> INFRINGEMENT ACTIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall inform University promptly in writing of any alleged infringement of the Patent Rights by a third party and of any available evidence thereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the term of this Agreement, Licensee shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the Patent Rights in the Field and in the Territory if Licensee has notified University in writing of its intent to prosecute; provided, however, that such right to bring such an infringement action shall remain in effect only for so long as the license granted herein remains exclusive.&nbsp;&nbsp;In furtherance of such right, University hereby agrees that Licensee may include University as a party plaintiff in any such suit, without expense to University.&nbsp;&nbsp;The total cost of any such infringement action commenced or defended solely by Licensee shall be borne by Licensee, and University shall receive a percentage of any recovery or damages for past infringement derived therefrom which is equal to the percentage royalty due University under Article 4.&nbsp;&nbsp;Licensee shall indemnify University against any order for costs that may be made against University in such proceedings.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If within six (6) months after having been notified of any alleged infringement, Licensee shall have been unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if Licensee shall notify University at any time prior thereto of its intention not to bring suit against any alleged infringer, then, and in those events only, University shall have the right, but shall not be obligated, to prosecute at its own expense any infringement of the Patent Rights, and University may, for such purposes, use the name of Licensee as party plaintiff.&nbsp;&nbsp;University shall bear all costs and expenses of any such suit.&nbsp;&nbsp;In any settlement or other conclusion, by litigation or otherwise, University shall keep any recovery or damages for past infringement derived therefrom.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.4</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Patent Rights shall be brought against University, Licensee, at its option, shall have the right, within thirty (30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.5</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In any infringement suit either party may institute to enforce the Patent Rights pursuant to this Agreement, the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, information, samples, specimens, and other</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">7.6</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">evidence upon request.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 8 </b>&#8211;<b> INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">8.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall at all times during the term of this Agreement and thereafter indemnify, defend and hold University, its trustees, officers, faculty members, employees and Affiliates (&#8220;Indemnified Parties&#8221;) harmless against all third party claims and expenses, including legal expenses and reasonable attorneys&#8217;&nbsp;fees, arising out of the death of or injury to any person or persons or out of any damage to property or the environment, and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from:&nbsp;&nbsp;(i) the production, manufacture, sale, use, lease, consumption or advertisement of the Licensed Technology, (ii) the practice by Licensee or its sublicensees of the Patent Rights and Know-How; or (iii) arising from or relating to this License Agreement.&nbsp;&nbsp;Licensee shall provide this defense and indemnity whether or not any Indemnified Party, either jointly or severally, is named as a party defendant and whether or not any Indemnified Party is alleged to be negligent or otherwise responsible for any injuries to person or property.&nbsp;&nbsp;The obligation of Licensee to defend and indemnify as set forth herein shall survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement.&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">8.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall obtain and carry in full force and effect liability insurance which shall protect Licensee and University in regard to events covered by Section 8.1 above, as provided below:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:12.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Commercial General Liability</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:21.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Coverage:&nbsp;&nbsp;Commercial General Liability, including, but not limited to, Products, Contractual, Fire, Legal and Personal Injury</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 21%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Limits:&nbsp;&nbsp;[***] Combined Single Limits for Bodily Injury and Property Damage</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:11.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Products Liability</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:21.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Coverage:&nbsp;&nbsp;Products Liability</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 21%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Limits:&nbsp;&nbsp;[***] upon first use of Licensed Technology in humans or first commercial sale, whichever is earlier</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 52pt;">The University of Pittsburgh is to be named as an additional insured with respect to insurance policies identified in Sections 8.2(a) and 8.2(b) above.&nbsp; Certificates of insurance evidencing the coverage required above shall be filed with University&#8217;s Innovation Institute, 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, PA&nbsp; 15260, within ten (10) business days from the Effective Date of this Agreement and on or before July 1 of each subsequent year during the Term of this Agreement.&nbsp; Such certificates shall provide that the insurer will give University not less than thirty (30) days advance written notice of any material changes in or cancellation of coverage.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">8.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATION AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING AND KNOW-HOW. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY.&nbsp;UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES FOR INDIRECT, SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS'&nbsp;AND EXPERTS'&nbsp;FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES FOR DIRECT DAMAGES ARISING OUT OF OR RELATED TO THE MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT.&nbsp;LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE SALES) WHICH IS LICENSED TECHNOLOGY<b>&nbsp;</b>HEREUNDER.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 9 </b>&#8211;<b> ASSIGNMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">This Agreement is not assignable without the prior written consent of University, which consent will not be unreasonably withheld, and any attempt to do so shall be null and void; except that, Licensee may assign this Agreement without the prior written consent to a third party, who is not a restricted party under US export control laws, in connection with the sale of all or substantially all of the assets to which this Agreement relates or in connection with a merger, acquisition, reorganization, or similar transaction involving the Licensee.&nbsp; For any permitted assignment to be effective,&nbsp; the assignee shall assume all obligations of Licensee set forth in this Agreement in writing, and such assumption agreement is promptly delivered to University upon execution.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 10 </b>&#8211;<b> TERM AND TERMINATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Term.&nbsp;&nbsp;The term of this Agreement shall be from the Effective Date until the later of (i) 20 years after first commercial sale of the Licensed Technology or (ii) expiration of the last Valid Claim of the Patent Rights; unless terminated earlier pursuant to Section 10.2 and 10.3 below.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">University shall have the right to terminate this Agreement, upon written notice, if:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee defaults in the performance of any of its obligations herein contained and such default has not been cured within sixty (60) days after receiving written notice thereof from University;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 80%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The practice of the Patent Rights or Know-How by Licensee or sublicensee is intentionally outside of the Field; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:16%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee may terminate this Agreement upon six (6) months prior written notice to University and upon payment of all amounts accrued or due to the University through the effective date of termination, including patent cost reimbursement pursuant to Section 6.2 hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10.4</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon termination of this Agreement, neither party shall be released from any obligation that accrued prior to the effective date of such termination.&nbsp;&nbsp;Licensee and any sublicensee may, however, after the effective date of such termination, sell all Licensed Technology which Licensee produced prior to the effective date of such termination, provided that Licensee shall pay to University the royalties thereon as required by Article 4 hereof and submit the reports required by Article 5 hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10.5</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The provisions of Articles 6-8, Sections 10.4 and 10,5, Article 11, and Sections 13.5 and 13.8 shall survive any expiration or earlier termination of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 11 </b>&#8211;<b> NOTICES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">11.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed to the address below or as either party shall designate by written notice to the other party, or if in accordance with Section 10.3.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 88pt;">In the case of University:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 124pt;">Innovation Institute</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 124pt;">University of Pittsburgh</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 124pt;">1st Floor Gardner Steel Conference Center</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 124pt;">130 Thackeray Avenue</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 124pt;">Pittsburgh, PA&nbsp; 15260</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 124pt;">ATTN: Director</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:72pt;">In the case of Licensee:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 88pt;text-indent:36pt;">Genprex, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 88pt;text-indent:36pt;">3300 Bee Cave Road</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 88pt;text-indent:36pt;">Suite 650-227</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 88pt;text-indent:36pt;">Austin, Texas 78746</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 88pt;text-indent:36pt;">ATTN: CEO</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">11.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any payments to University hereunder by wire transfer shall be directed as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 52pt;text-indent:-36pt;">Bank: [***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">ABA Routing No.: [***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Account No.: [***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Mellon SWIFT Code: [***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 218pt;text-indent:-203pt;">Reference Code: [***]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">11.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Licensee shall be responsible for all applicable fees and costs relating to any wire transfer, to include translation fees, without any deduction of such fees from amounts due to the University pursuant to this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">11.4</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All invoices to Licensee generated by University under this Agreement will be sent electronically, via e-mail, in PDF format, unless instructed otherwise by Licensee in writing.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 12</b>&#8211;<b> AMENDMENT, MODIFICATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 52pt;text-indent:36pt;">This Agreement may not be amended or modified except by the execution of a written instrument signed by the Director of the University of Pittsburgh Innovation Institute, his successor, or other designated University employee having signatory authority, and Licensee&#8217;s Chief Executive Officer.&nbsp; In connection with any agreed upon amendment or modification of this Agreement pursuant to this Article 12, Licensee shall be required to pay an Amendment Fee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 13 </b>&#8211;<b> MISCELLANEOUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.1</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania.&nbsp;&nbsp;The forum for any action relating to this Agreement, including those brought against individuals such as University employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United States District Court for the Western District of Pennsylvania.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.2</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.3</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult, with their legal counsel and/or other advisors with respect to the Patent Rights, Licensed Technology, and the terms of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.4</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The parties agree that this Agreement constitutes an arm&#8217;s length business transaction and does not create a fiduciary relationship.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.5</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Except as provided herein, nothing contained in this Agreement shall be construed as conferring upon either party any right to use in advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing.&nbsp;&nbsp;Without the express written approval of the other party, neither party shall use any designation of the other party in any promotional activity associated with this Agreement or the Licensed Technology.&nbsp;&nbsp;Neither party shall issue any press release or make any public statement in regard to this Agreement without the prior written approval of the other party. Licensee may use the name of the University in routine business correspondence, or as needed in appropriate regulatory submissions and disclosures made under state and federal securities laws, and may state the fact that the University is the licensor of the licensed Patent Rights and Know-How without the prior express written consent of the University.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.6</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee agrees that with respect to the performance of this Agreement or the practice of the rights granted by the University hereunder, it shall comply with any and all applicable United States export control laws and regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department&#8217;s Office of Foreign Asset Controls.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.7</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each Party agrees that in connection with this Agreement that it will abide by applicable laws and regulations.&nbsp;&nbsp;No Party will offer, promise or give, directly or indirectly, anything of value to any government official, political party official, political candidate, or employee thereof or to any third party while knowing that such item of value or any portion thereof may be offered, promised, or given to a government official, political party official, political candidate, or employee thereof for the purpose of obtaining or retaining business.&nbsp;&nbsp;Each Party specifically agrees that in connection with this Agreement, it will take no action, or omit to take any action, which would cause another party to be in violation of the applicable laws of the United States, including the U.S. Foreign Corrupt Practices Act and/or any local laws regarding bribery as well as any US anti-boycott laws.&nbsp;&nbsp;In addition, the Parties represent and certify that neither the Parties nor their officers, board members nor agents involved in the performance of this Agreement have been convicted of crimes involving theft, fraud, bribery, corruption or moral turpitude and that each is not now listed by any government agency as being debarred, suspended or proposed for debarment or suspension.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.8</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If Licensee challenges the validity or enforceability of University&#8217;s Patent Rights or University&#8217;s ownership of the Patent Rights anywhere in the world, the Licensee shall continue to pay to University all royalties and other financial obligations required under this Agreement during such challenge, to include patent costs and fees, in order to keep the Agreement effective.&nbsp;&nbsp;If any such challenge by Licensee is unsuccessful, the running royalty rates and any Non-Royalty Sublicense Income rate set forth in Section 4.1 above shall automatically double in value, to include all minimum royalties and floors and Licensee shall reimburse the University for all fees and costs associated with defending such action, including but not limited to attorneys fees and expert fees. The effective date of such increase in royalty rates shall be the date of the first court order or date of issuance of a re-examination certificate (or foreign equivalent thereof) declaring any claim or claims of any of the Patent Rights as valid or enforceable Within thirty (30) days prior to filing any such challenge, Licensee shall provide the University with written notice of its intent to make such challenge detailing its allegation(s) along with specific and detailed facts supporting those allegations of invalidity or unenforceability of University&#8217;s Patent Rights.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.9</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the remaining provisions shall not in any way be affected or impaired thereby.&nbsp;&nbsp;In the event any provision is held illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as is practical, implements purposes of the provision held invalid, illegal or unenforceable.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.10</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Failure at any time to require performance of any of the provisions herein shall not waive or diminish a party&#8217;s right thereafter to demand compliance therewith or with any other provision.&nbsp;&nbsp;Waiver of any default shall not waive any other default.&nbsp;&nbsp;A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly authorized officer of the party making such waiver.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:14.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">13.11</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall mark all Licensed Technology with applicable U.S. and foreign patent numbers in accordance with the applicable laws of the countries in which Licensed Technology is used or sold.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[remainder of page intentionally left blank]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind the party to this Agreement and have set their hands and seals as of the date set forth on the first page hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54%;margin-left:0pt;margin-right:auto;">

		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">UNIVERSITY OF PITTSBURGH &#8211;&nbsp;OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Evan Facher</i></p>
			</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evan Facher, Ph.D., MBA</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Innovation Institute</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vice Chancellor for Innovation and Entrepreneurship</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 16, 2022</p>
			</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:5.9%;">&nbsp;</td>
			<td style="vertical-align:middle;width:93.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:43.2%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54%;margin-left:0pt;margin-right:auto;">

		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GENPREX, INC.</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Rodney Varner</i></p>
			</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rodney Varner</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 29, 2022</p>
			</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:5.9%;">&nbsp;</td>
			<td style="vertical-align:middle;width:93.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:43.2%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT A</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>PATENT RIGHTS FOR EXCLUSIVE LICENSE AGREEMENT BETWEEN</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>THE UNIVERSITY OF PITTSBURGH AND GENPREX, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT B</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SAMPLE ROYALTY REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT C</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SAMPLE PROGRESS REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT D</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>KNOW-HOW </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex_461280.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">EXHIBIT 99.1</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 16pt; text-align: center;"><b>Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies &amp; Treatments for Diabetes</b>&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i>Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex</i>&#8217;<i>s Gene Therapy Program in Diabetes to be Showcased.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">AUSTIN, Texas &#8212; (January 4, 2023) &#8212;&nbsp;Genprex, Inc.&nbsp;(&#8220;Genprex&#8221; or the &#8220;Company&#8221;) (NASDAQ:&nbsp;GNPX), a&nbsp;clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex&#8217;s gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">&#8220;ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community. The data further support the potential of Genprex&#8217;s novel gene therapy being developed for the treatment of Type 1 diabetes to change the trajectory of this devastating disease,&#8221; said Mark Berger, MD, Genprex&#8217;s Chief Medical Officer. &#8220;Using the expression of Pdx1 and MafA transcription factors, this approach has been shown first in mice and then in non human primate studies to lead to the creation of new beta-like cells that produce insulin and may provide long-term replacement of beta-cells.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas. In models of Type 1 diabetes, these genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#8217;s immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that using a similar approach the exhausted beta cells will be rejuvenated and replenished.&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Presentation Details:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Abstract Number:</b>&nbsp;203</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Abstract Title:</b>&nbsp;Pancreatic Intraductal Infusion of Adeno-Associated Virus To Treat Non-Human Primates in a Toxin-Induced Diabetes Model</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Format:</b>&nbsp;Oral Presentation</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Presenter:</b>&nbsp;Ranjeet Kalsi, DO,&nbsp;representing the laboratory of&nbsp;&nbsp;George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery, University of Pittsburgh School of Medicine</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Time/Date:</b>&nbsp;1:45 pm Central European Standard Time on Saturday, February 25, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">The abstract will be made available on the ATTD conference website at&nbsp;https://attd.kenes.com.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>About Genprex, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex&#8217;s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex&#8217;s oncology program utilizes its proprietary, non-viral ONCOPREX&#174; Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company&#8217;s lead product candidate, REQORSA&#174; (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer. Genprex&#8217;s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. In models of Type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#8217;s immune system. In a similar approach used in Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are rejuvenated and replenished.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">For more information, please visit the Company&#8217;s web site at&nbsp;www.genprex.com&nbsp;or follow Genprex on&nbsp;Twitter,&nbsp;Facebook&nbsp;and&nbsp;LinkedIn.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Cautionary Language Concerning Forward-Looking Statements</b>&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex&#8217;s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under &#8220;Item 1A &#8211; Risk Factors&#8221; in Genprex&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex&#8217;s clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex&#8217;s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex&#8217;s future growth and financial status; Genprex&#8217;s commercial and strategic partnerships, including those with its third party manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex&#8217;s intellectual property and licenses.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Genprex, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">(877) 774-GNPX (4679)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>GNPX Investor Relations</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">investors@genprex.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>GNPX Media Contact</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">Kalyn Dabbs</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;">media@genprex.com</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>ex_461281.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: right;">EXHIBIT 99.2</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">AUSTIN, Texas &#8212; (January 5, 2023) &#8212; Genprex, Inc. (&#8220;Genprex&#8221; or the &#8220;Company&#8221;) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors. The preclinical technology, GPX-003, is believed to work by rejuvenating diminished beta cells to increase insulin expression by introducing transcription factors controlled by an insulin promoter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#8220;This marks the Company&#8217;s third technology license this year supporting our diabetes program, demonstrating the continued strengthening of our intellectual property portfolio, our diabetes program, and our position as a lead innovator in emerging diabetes gene therapies,&#8221; said Rodney Varner, President and Chief Executive Officer of Genprex. &#8220;We are thrilled to have secured multiple cutting edge technologies from Pitt that expand our diabetes gene therapy program and specifically target Type 1 and Type 2 diabetes.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#8220;With this license agreement, Genprex now has a drug product candidate for Type 1 diabetes, GPX-002, that uses a glucagon promoter specifically optimized for use in alpha cells and another drug product candidate, GPX-003 for Type 2 diabetes, that uses an insulin promoter optimized for beta cells,&#8221; said Mark Berger, MD, Chief Medical Officer of Genprex. &#8220;Both product candidates are based on the same general gene therapy approach under Genprex&#8217;s original license that is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. Each of these technologies may have the potential to provide long-term efficacy and to change the course of this disease for the millions of patients around the world with diabetes.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">All of the diabetes technologies licensed from Pitt by Genprex are out of the laboratory of George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery at the University of Pittsburgh School of Medicine.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Genprex recently announced a license agreement with the University of Pittsburgh for a preclinical technology that transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes, a technology that could be complementary to the Company&#8217;s GPX-002 diabetes technology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#8217;s immune system. GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Earlier studies in diabetic mouse models showed that an earlier version of GPX-002 restored normal blood glucose levels for an extended period of time, typically around four months. It is believed that the duration of restored blood glucose levels in mice could translate to decades in humans. Preliminary data from a more recent study in a non-human primate model of Type 1 diabetes also have been promising and are expected to be presented at a scientific meeting during the first quarter of 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">More than 537 million people around the world have diabetes, and in the U.S. alone, there are 37.3 million people with diabetes. In 2021, diabetes took the lives of more than 6.7 million people.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>About Genprex, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex&#8217;s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex&#8217;s oncology program utilizes its proprietary, non-viral ONCOPREX&#174; Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company&#8217;s lead product candidate, REQORSA&#174; (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer. Genprex&#8217;s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body&#8217;s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">For more information, please visit the Company&#8217;s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Cautionary Language Concerning Forward-Looking Statements </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex&#8217;s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under &#8220;Item 1A &#8211; Risk Factors&#8221; in Genprex&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex&#8217;s clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex&#8217;s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex&#8217;s future growth and financial status; Genprex&#8217;s commercial and strategic partnerships, including those with its third party manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex&#8217;s intellectual property and licenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Genprex, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(877) 774-GNPX (4679)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>GNPX Investor Relations</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">investors@genprex.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>GNPX Media Contact</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Kalyn Dabbs</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">media@genprex.com</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>gnpx-20221229.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/5/2023 9:39:06 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:gnpx="http://www.gnpx.com/20221229" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gnpx.com/20221229">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20221229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20221229_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20221229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.gnpx.com/20221229/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="gnpx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>gnpx-20221229_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/5/2023 9:39:08 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.gnpx.com/20221229/role/statement-document-and-entity-information" xlink:href="gnpx-20221229.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.gnpx.com/20221229/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>gnpx-20221229_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/5/2023 9:39:07 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Ex Transition Period</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>gnpx-20221229_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 1/5/2023 9:39:09 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.gnpx.com/20221229/role/statement-document-and-entity-information" xlink:href="gnpx-20221229.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.gnpx.com/20221229/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139641390950400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">GENPREX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Dec. 29,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">90-0772347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">3300 Bee Cave Road, #650-227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">78746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">537-7997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GNPX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity, Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001595248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>gnpx20230103_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gnpx-20221229.xsd" xlink:type="simple"/>
    <context id="d20238K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2022-12-29</startDate>
            <endDate>2022-12-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20238K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20238K">0001595248</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20238K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20238K">2022-12-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20238K">GENPREX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20238K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20238K">001-38244</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20238K">90-0772347</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20238K">3300 Bee Cave Road, #650-227</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20238K">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20238K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20238K">78746</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20238K">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20238K">537-7997</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20238K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20238K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20238K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20238K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20238K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K">GNPX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20238K">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d20238K">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MN,HVY]F%EE&Z(=Y(#=OK]'3/&;B5:0#/MU+JRX798^=_D8S^ U!+ P04
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M2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @  84E5B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @  84E5@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  !A256"%K+:>X    K @  $0
M    @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  !A256F5R<
M(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM
M;%!+ 0(4 Q0    (  &%)59;=(4L700  "X1   8              " @0T(
M  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  !A256GZ ;
M\+$"  #B#   #0              @ &@#   >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    (  &%)5:7BKL<P    !,"   +              "  7P/  !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    (  &%)58ZJJ+G0 $  #P"   /
M  "  640  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  !A256)!Z;HJT
M  #X 0  &@              @ '2$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  !A25699!YDAD!  #/ P  $P
M@ &W$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   !%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="gnpx20230103_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gnpx.com/20221229/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="gnpx20230103_8k.htm">gnpx20230103_8k.htm</File>
    <File>ex_460640.htm</File>
    <File>ex_461280.htm</File>
    <File>ex_461281.htm</File>
    <File>gnpx-20221229.xsd</File>
    <File>gnpx-20221229_def.xml</File>
    <File>gnpx-20221229_lab.xml</File>
    <File>gnpx-20221229_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gnpx20230103_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 23
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "gnpx-20221229_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gnpx20230103_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gnpx-20221229_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gnpx-20221229_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gnpx-20221229.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 27,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "gnpx",
   "nsuri": "http://www.gnpx.com/20221229",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20230103_8k.htm",
      "contextRef": "d20238K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.gnpx.com/20221229/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "gnpx20230103_8k.htm",
      "contextRef": "d20238K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity, Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.gnpx.com/20221229/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-23-000499-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-000499-xbrl.zip
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MD^VFEZTYV=IN&JA,C&2HTG764MF'L??R#6.U6)Y,POIO0703([M?)/BO31+
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M/&CFZ.GTI+)/:^V[EE<J\@*5;G4*UD9SW/MT-GAHCEMDYU2-B^X$;S >[%Y
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M<Z]TJD?':V)4\VYE4LLL)PS28FFT$P-_;]9,L:37 CM:$S\H2D_H#@!<A"U
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M$J3K\W^%ONCH_A@LDK$%DRZ<7>US\0)[@+!TID@7K!Q)QM <26_.JW8HR(N
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M1TUEDA0S($Q!9#J- 1TN.&H&]D5/3TUAEDH'[/+>(PZ/DA JT*D*JJQXNEK
MN A]Q12#HNPA<L](59?Y1L"APUXD</X1+R94DL3DF)_'F$2!Q5=LQ2S< )8B
M%G6%P@.OO[6.GVBI@??8^3S5A;,<O#=:A=7*I&D!*POMA- F"Z'V0-('L0B+
MHD5I\!DCW"^J$>ZFP'65]7TQ@KW:%B2);X(5'+L4MTF087\#G7P#EUVA8:2C
MSL[=X>1##"<[PE>IE\ 737S.#DCHKE11W)[CVS<JC!<\V41=(4HW!JDG%SA5
M&8+$+&)[!$FU9AI]@EV]5AKVZ5,(/BUORP*U7H9CWJKP1FT3)!BE1!#[*%/P
MIW)&4L<_-IA_M =M/X@S5 1 ;8@LV)A*ECEENF::G\DRP-SA[!9#Z=PPK40Q
M63,4QJA3V0R^$4\.MH@#I6L5JR\H5,!_M#X%5WJS"#>VU*6HK!438+]@8_ET
M&GB!3LM1R,Q("9\INI'-5_@(ZJ4N&V=O#=+7XHG< IX S"3PS()K53G+#=F>
MVOS2TJ8"7T(E<VEZS_B%DDU>(X%IGG/%3 D50S^ ]TBS7(6/&W3\@<.OK^,_
MF\Q_6HOW9C7!Y$^7$6TSG63S)=!<<P,7G9!:UX_@>FKMDBAM([%NA%9F\FB:
M(W8@[0ZD?6^0]HLZ2/NB-W8'8W$Q/!^YAY==0\N-D 0O6H32+CL;)54Q9Y$
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M/*2\&H^9E89-%!0! B9GN /'VRVSR_"Z2B'G:HP[ 7&:^)S83_$I710("=&
M3T%Q,@#H2HJ*"N/;KJ7%GTMC^VVJ/]JBIA:'1?[[!RX<!U2AJ:<[PG_F$=[?
M:]$1EBMNKT=\@E&]O%(5-?^N8_W%KJ(7NHF%(PYA/JB[YS)TQ'& ]L$IV5DH
M,"Y(>X0/?;*0.FKYDTOT[K>'7";W(9=*A=Z7S[_Y9$_QJ*<5<N&L."":21!A
M6BV<C1"-6KR0+*?WL0^ST2>=3[\Q[X_(XN]._Y^J[NSMO&K-X;]?]Z*'%1:&
MM7=*3J?DM%[)Z0YSIX-\;SH(A=ZY-%N>KNMAB@Z:60Y3H>A#8R$WAQT^% [
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M?=95_':^3*&/GPO<@QON[=;9(8BK,])*\(_^H-?5CM\(*WYOMT69!>@B6ZU
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MW+&;C68W>[NMX3?'((=S8#22Z36#)R!]:85\39>D&DO239(*[G$K45=#S2I
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MT/&CCA_]$7[T_E'PHU'O[.+4%</S3[U3H.RA>W$^''<$W!%P1\!?(N##QT3
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MI2,RL: 0V+%Y<M9%\F6 T#.5D6'9*:.=I:TRPBW':3U+N1>5F8FGNYC&@^&
M@5!0!&P*)RMLBI: ,<HD/X7/++)G%;=!C3"ZAD2YMXE6E^E:8?@,8-J"%@O+
M:[H3N*#-IQA([M==&UOCH,M&(-F]E+KR40WCLB6$)%2#GQFF;.HXE>LX+ TF
M,N$9C+'4_ZR@BI6<C$,IK+W%M5:XK<.:SCCIL[GV4*4L0@RYG]B;B*V)A&$>
MS,!,5S4+:!D@T)FNN32.ZQ [S51-/H,O?VNTBYFRE//[Q4:6%^J_[.C@3UU\
M^X=GSW;$LV=/^G1-66P_^?[9\YVO=[OTZVN:=GEF$"JH7W:I4C/_J^I<I^7]
MOU9Z&_<.TJ1HNIX@J0D10$F^JH[?R')AQ(D<C_U76[.BW6ZPZ<JYZ=OAU:B_
M/ 7>>$K]IYX^MX>O^(,:HS  _S_#_@M02P,$%     @  84E5CQ[E] )$
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ME>NLN79XV,/D^(TRE5,?Q#7&>W'V(2MJK^^4>*OQL5<B6#&&JLA"9"%.M9S
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M2'X;D7D#   N#@  $0   &=N<'@M,C R,C$R,CDN>'-DS5=1;]LV$'X?L/_
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M+@  %0   &=N<'@M,C R,C$R,CE?9&5F+GAM;,U:76_B.!1]7VG_0S;['-+
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M-)MH:U[Q4>)4FPAJ7N5A8'$?>:G^3]IDV!\?#_?5'_7_TO+._U!+ P04
M"  !A256*$.YXB(&  #,/@  %0   &=N<'@M,C R,C$R,CE?;&%B+GAM;,V;
M76_;-A2&[P?L/W#>S09449RL&QPT+8(T+8REC1$[V+!B&&2)MHE)/"Y%-_:_
M'TG)'[))65),:C>)8AV=]_@]CT124MZ\6R8Q^H992H!>=[IGYQV$:0@1H=/K
MSM/0NQG>]OL=E/* 1D$,%%]W*'3>O?W^NS<_>-Y'3#$+.([0>(5&LP6-,'L/
M"48#8#R(D8>Z_FO_XOSB$O6N+GM7Y[^AP2?/DT?'A/Y[)7^,@Q0C405-U9_7
MG1GG\RO??WY^/EN.67P&;"I2G%_ZZ^A.'B[W1GQSP&[P:S_;N0D]2/U\J6*[
MO5[/5WLWH2G1!8JD7?_/3_?#<(:3P"-46A+*6E)RE:H/[R$,N/+QZ%= Q@CY
ME[<.\^1'7O?"N^R>+=.HLS&.08P?\03)WT^/?:-BSY<1/L53V:7[8(QC4;%*
M,6-XHC\N9JQPF*RB)ZOH_BJK^%&7C:_F HV4)/,8=_P7UCG C$!T1T]<L#ZM
MA<J'/&#<1NV'B4]:_0C$27O:N@]3GK9B<>7")Z[X(.5)*_Z,3TS&?L)35=N@
M3'Y88J7:8AES+[;R,)FNY"*JU/)+]DY:O.18#$ [5\D8PH/RT_5(D>+P; K?
M_ @3.4)UO_XB-[UL4U4O_OSGCG+"5V),"PA=RZERKSNFW5DUL1P,@.U_R_(4
M7KSK5B4;#NUE.(4%"[-A4BC)D1Q3[VG8>9MIH2^9VM]O_&TQQ3)OV-JY@(5'
MZL@C_!#$>#CGQ>\P89"46 7'/,B^DI!01IZPL??B[(DSW9LE236]-434;.]>
M%ML=5G)HW6>IZ+;+)M.@@AO6>OT>PD6"*>_3";!$S='$U0;W.4YTC:\27I."
MLI2VD5AKHQUQ]$7*(Z7O%I!*YD)=UURB,PK&,:Z&32'TY<BH=.W@HJ1;)Z7H
MIYD2C5'6"1D)@1(J=G<W)$&F<-7]5TBJM=+O@E-PS +K?=VL&M^+V79)@[5Q
M#3M=R.6NY9FLF#U$2 JWTGV]C5#9'VL\9+.61SPE*6<!Y9^#1(=#65BCE4$Q
ME9L5PBNT5452MH65@L%"J.J-91#Z- 0V!Z;&FR$7'-["@G*VNH7(S$6EHQIA
M4IK9%36%(EXA508"AO)2D*RE!92JN0X-[;0,V@<2X\^+9(R9D:K#D$8(;=.X
MXD4JHDRR!2PTMD$5/RPW?!0L^Y$8Y,B$9,\3CG3_2'PC% PY77$AY%%1OSU*
MCMD+M7VSS,]-% F+T_R77#!WC>R4Q#;B1I//%3.YYF8#J3L<#[2- :?,5JCE
MEQM6;L7F QO!L_D>MS'R)9QLLSFG1$K+J8D4;X\0C9TZ/DP^N:%#37\>V(#!
M-Y(]\BYMJB'\)9SLI70.RV8BNZZ@/6),[NJP*;7-#3L#2'D0_T7FI<NBLN"7
M<%-(Z)R:3!T)^;86/J6^ZH@I,<P:+_+B=L-P8"!$M[LF$[LI;%.@QA4IYK[G
M6J?@F 7VGK"*]L2#&5#S\M444O<9ZUX:ZP]9I1Y2@FVL2XRN014[K/7[#T8X
MQ_06DF1!\^6/[O%J:5S-SFMSV6Y_+HJ*JDX1*/<0*IMC#88AQ"0DG-#I)S$'
M822(-228@VIB<)C(-@-;1;26= I B750S1-KK1\P+)'#HG[UR$Z^E,4>)A/M
M"' \N"8*YH2VD1#*7K@CC3)MI,2=PE'!5*CGEBM8^FFZP*P6,L9#7@;.05KG
M^&05_&\H,ONL9^F(@?9&'APNQ,"WZEZ,1X1KW]0QA=0==?;2V"9$B2"8H.[%
M3^.?T5K>[;ACL@ZJ>&*MZ2,6R']9&:Z2,>AF&MK]-=M=R&&]UYD8RM2<MECO
M%1PUP?H9?;<,9\(C;'CSHBRLX9F]F\KZC#+71&M1]R]>E#H(5:VQ?&/Q+L%L
M*A#\R."9S\2(,P_HRGAGL32ZT:U%;497]Q;7XBA31[E\"[<6RXV%FH[99F8I
MKELT)7(%G+T[9@;&&-J,EH-TSE!9HJUT_FI?&YR8_80Z1EDCY$9,5B,Y8?T0
M!U,-%MK]-5DHY+ -P$8,236G+==[!4=-L'SZWPI1%L1]L119_H[-@X4AKM&)
MOY?+U5F?RR*EBX1P"Z>\R4:H[,\!#SM?XEYLO=U^1++_E!:?_ =02P,$%
M  @  84E5NI^@[N/!   G2\  !4   !G;G!X+3(P,C(Q,C(Y7W!R92YX;6S=
M6M&.VC@4?:_4?\BFSR$$.KL%E5:(F59HF0X:J':U+RN3&+#JV-0V0_C[O4Z
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M5:FP<NT2-$?R5;.';">#(XEJM7%M)X4CV:J%46ZGAR/I:ITW;R>&(^FI[3&
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M$F6F :V YA.&],BO1/CMV/F7<+ <+'BYUBH\U@ GX"337_O!M#P.IC".YRV
M"MA(^&2N%0_G9)?Q)#]K,%?R@8B _V!X,+L(%G9-2XDNW5F=8/K"AZ?&Q#M*
MAD3#(7>B0.D[W<OM\OESE#V,%8O8%&\&&@<*)M(I(P*Q)OP:"#_&HO4)1QY
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MQ$D @PSY38!^AP,H#F ]%=9?K%L7>3]WJ&6<&Z3PW^#!X%L+A9_J+3P;. K
M.?2-RC*N%IH1,F/<^19+!(GG:$F4-7>0@@&")>&N@ 0K$68=G93.0"0:+7E@
M,@SXOP]J:LR]80H/1 C03*>>C+,E?;SB@O;R78$^S,#D\59Y9TD]DROV(L5W
MPG2JT4!J\%GM:=W$!!;;M%7)"8%92$(8Q7<\%2,V1!U@3=6$4WD\7O^)ST$.
M56S,$SHG(!2N'(%A,_J#]/8$AIO$DV2 M(5RNF#!9B@I7"<:&V9B:#3<(!ZD
MPX$EQ10#'PFS0X5\AOK"JJFLB<(CRQ-AU,.*I<9%&L<)6-R$.7P$&!C9"UG(
MT9E)+*D$X_BW5JE6J]$?&VDL3)#E6>BNZ< 3(%S,0B/@ $),@8?QHF@>$+UA
M9&4<G!03BS#7SKN.3B]\_W#?7@GD56(S@W"&N4WKOV,V Q'?J)$_I3/4*?2I
MV'IWBEDY _)+E?H@9A88"-QFT*B.QV7J91K>T8O!;E?_%7R*JAQMD?219>A8
M2[I2JT;-)4(PQ[)1BI$?81I7#'GL@80-P8+!DZQ3BP,LW-=5US;?GG%O2[A^
MT@FX=')F$W.QA+*\FH>W4@\!=#TJKMNC(S-1NCH0;JZ-'^I 2#3'0<BT#S"4
M!F<:76=4!?"$^]<J!D8B2'7@W1BW/@SQ]J7$B*'V)+)8"PO- :QK8I'*(?H&
MID-5J(0C,!&#;WD2+"N(<4#L1*Z%UL*L3PMQC7X5S#+,G 3R^'01MYE&7*X8
M4#2?BP'S%%\?LFD)_4&.QGHI<O,#XZ&ESH]5@+0BU&36#P?'6\5 (WC5C9/^
MUA*OTUD6-J#ZBYJZEYH"HHM1@+;2N$!A5EFD9?S&X[S%*(!I!(AQ&XB<844^
MX4"8K1Z0&./DZHS'6$H>0>#GY>Z/0JE5 BSH($F8805F(@)KPF&8*:0,I/$R
M85QPIM&YQ(W2L1R P:[7*G4S"K1VZ'+LB/7,]6=X"4=RZH[@2B\9@3% U@7
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MT<0[^2]02P$"% ,4    "  !A2564FB^0#=!  "8)P( #0
M@ $     97A?-#8P-C0P+FAT;5!+ 0(4 Q0    (  &%)58(9 1>L@X  " V
M   -              "  6)!  !E>%\T-C$R.# N:'1M4$L! A0#%     @
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F>#(P,C,P,3 S7SAK+FAT;5!+!08     "  ( /H!   0BP     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
